6. Sinovac Biotech ( SVA), a holding company, is an integrated China-based biopharmaceutical company focusing on vaccines against infectious diseases. Sinovac will announce third-quarter results Nov. 14. Net income for the third quarter of 2011 is estimated at $1.36 million compared to a net loss of $300,000 in the year ago quarter, as per analysts polled by Bloomberg. Sales are forecast at $12.1 million, up 27% from $9.55 million in the third quarter of 2010. Gross margin for the quarter is seen increasing to 73% from 68.26% in the year-earlier quarter. Operating profit is seen swinging to positive $2.23 million from a $740,000 operating loss in the year-ago quarter. Of the three analysts covering the stock, 33% recommend a buy and the rest suggest a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 78.9% to $3.90 from current levels over the next 12 months.